FXR1 regulates transcription and is required for growth of human cancer cells with TP53/FXR2 homozygous deletion

  1. Yichao Fan
  2. Jiao Yue
  3. Mengtao Xiao
  4. Han Han-Zhang
  5. Yao Vickie Wang
  6. Chun Ma
  7. Zhilin Deng
  8. Yingxiang Li
  9. Yanyan Yu
  10. Xinghao Wang
  11. Shen Niu
  12. Youjia Hua
  13. Zhiping Weng
  14. Peter Atadja
  15. En Li
  16. Bin Xiang  Is a corresponding author
  1. Novartis Institute for BioMedical Research, China
  2. Novartis Institutes for BioMedical Research, China
  3. Tongji University, China

Abstract

Tumor suppressor p53 prevents cell transformation by inducing apoptosis and other responses. Homozygous TP53 deletion occurs in various types of human cancers for which no therapeutic strategies have yet been reported. Based on TCGA database analysis, TP53 homozygous deletion locus mostly exhibits co-deletion of the neighboring gene FXR2, which belongs to the Fragile X gene family. Here, we demonstrate that inhibition of the remaining family member FXR1 selectively blocks cell proliferation in cancer cells containing homozygous deletion of both TP53 and FXR2 in a collateral lethality manner. Mechanistically, in addition to its RNA-binding function, FXR1 recruits transcription factor STAT1 or STAT3 to gene promoters at the chromatin interface and regulates transcription thus, at least partially, mediating cell proliferation. Our study anticipates that inhibition of FXR1 is a potential therapeutic approach to targeting human cancers harboring TP53 homozygous deletion.

Article and author information

Author details

  1. Yichao Fan

    Epigenetic Discovery, Novartis Institute for BioMedical Research, Shanghai, China
    Competing interests
    No competing interests declared.
  2. Jiao Yue

    Epigenetic Discovery, Novartis Institutes for BioMedical Research, Shanghai, China
    Competing interests
    Jiao Yue, Jiao Yue is an employee for Novartis, Inc., where part of the study was conducted..
  3. Mengtao Xiao

    Epigenetic Discovery, Novartis Institutes for BioMedical Research, Shanghai, China
    Competing interests
    Mengtao Xiao, Mengtao Xiao is an employee for Novartis, Inc., where part of the study was conducted..
  4. Han Han-Zhang

    Epigenetic Discovery, Novartis Institutes for BioMedical Research, Shanghai, China
    Competing interests
    Han Han-Zhang, Han Han-Zhang is an employee for Novartis, Inc., where part of the study was conducted..
  5. Yao Vickie Wang

    Epigenetic Discovery, Novartis Institutes for BioMedical Research, Shanghai, China
    Competing interests
    No competing interests declared.
  6. Chun Ma

    Epigenetic Discovery, Novartis Institutes for BioMedical Research, Shanghai, China
    Competing interests
    No competing interests declared.
  7. Zhilin Deng

    Epigenetic Discovery, Novartis Institutes for BioMedical Research, Shanghai, China
    Competing interests
    No competing interests declared.
  8. Yingxiang Li

    Department of Bioinformatics, Tongji University, Shanghai, China
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0835-9280
  9. Yanyan Yu

    Epigenetic Discovery, Novartis Institutes for BioMedical Research, Shanghai, China
    Competing interests
    Yanyan Yu, Yanyan Yu is an employee for Novartis, Inc., where part of the study was conducted..
  10. Xinghao Wang

    Epigenetic Discovery, Novartis Institutes for BioMedical Research, Shanghai, China
    Competing interests
    No competing interests declared.
  11. Shen Niu

    Epigenetic Discovery, Novartis Institutes for BioMedical Research, Shanghai, China
    Competing interests
    Shen Niu, Shen Niu is an employee for Novartis, Inc., where part of the study was conducted..
  12. Youjia Hua

    Epigenetic Discovery, Novartis Institutes for BioMedical Research, Shanghai, China
    Competing interests
    Youjia Hua, Youjia Hua is an employee for Novartis, Inc., where part of the study was conducted..
  13. Zhiping Weng

    Department of Bioinformatics, Tongji University, Shanghai, China
    Competing interests
    No competing interests declared.
  14. Peter Atadja

    Epigenetic Discovery, Novartis Institutes for BioMedical Research, Shanghai, China
    Competing interests
    Peter Atadja, Peter Atadja is an employee for Novartis, Inc., where part of the study was conducted..
  15. En Li

    Epigenetic Discovery, Novartis Institutes for BioMedical Research, Shanghai, China
    Competing interests
    No competing interests declared.
  16. Bin Xiang

    Epigenetic Discovery, Novartis Institutes for BioMedical Research, Shanghai, China
    For correspondence
    bin.xiang@novartis.com
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6973-100X

Funding

Novartis (Research)

  • Bin Xiang

Novartis (Postdoc program)

  • Yichao Fan

The authors declare that there was no funding for this work.

Ethics

Animal experimentation: All the procedures related to animal handling, care and the treatment in the study were performed according to the guidelines approved by the Institutional Animal Care and Use Committee (IACUC) of WuXi AppTec following the guidance of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). The approved protocol number is R20150728-Mouse and Rat. The animals were daily checked for any effects of tumor growth and treatments on normal behavior such as mobility, food and water consumption, body weight gain/loss, eye/hair matting and any other abnormal effects. Death and observed clinical signs were recorded.

Copyright

© 2017, Fan et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,067
    views
  • 457
    downloads
  • 28
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Yichao Fan
  2. Jiao Yue
  3. Mengtao Xiao
  4. Han Han-Zhang
  5. Yao Vickie Wang
  6. Chun Ma
  7. Zhilin Deng
  8. Yingxiang Li
  9. Yanyan Yu
  10. Xinghao Wang
  11. Shen Niu
  12. Youjia Hua
  13. Zhiping Weng
  14. Peter Atadja
  15. En Li
  16. Bin Xiang
(2017)
FXR1 regulates transcription and is required for growth of human cancer cells with TP53/FXR2 homozygous deletion
eLife 6:e26129.
https://doi.org/10.7554/eLife.26129

Share this article

https://doi.org/10.7554/eLife.26129

Further reading

    1. Cancer Biology
    2. Immunology and Inflammation
    Sofia V Krasik, Ekaterina A Bryushkova ... Ekaterina O Serebrovskaya
    Research Article

    The current understanding of humoral immune response in cancer patients suggests that tumors may be infiltrated with diffuse B cells of extra-tumoral origin or may develop organized lymphoid structures, where somatic hypermutation and antigen-driven selection occur locally. These processes are believed to be significantly influenced by the tumor microenvironment through secretory factors and biased cell-cell interactions. To explore the manifestation of this influence, we used deep unbiased immunoglobulin profiling and systematically characterized the relationships between B cells in circulation, draining lymph nodes (draining LNs), and tumors in 14 patients with three human cancers. We demonstrated that draining LNs are differentially involved in the interaction with the tumor site, and that significant heterogeneity exists even between different parts of a single lymph node (LN). Next, we confirmed and elaborated upon previous observations regarding intratumoral immunoglobulin heterogeneity. We identified B cell receptor (BCR) clonotypes that were expanded in tumors relative to draining LNs and blood and observed that these tumor-expanded clonotypes were less hypermutated than non-expanded (ubiquitous) clonotypes. Furthermore, we observed a shift in the properties of complementarity-determining region 3 of the BCR heavy chain (CDR-H3) towards less mature and less specific BCR repertoire in tumor-infiltrating B-cells compared to circulating B-cells, which may indicate less stringent control for antibody-producing B cell development in tumor microenvironment (TME). In addition, we found repertoire-level evidence that B-cells may be selected according to their CDR-H3 physicochemical properties before they activate somatic hypermutation (SHM). Altogether, our work outlines a broad picture of the differences in the tumor BCR repertoire relative to non-tumor tissues and points to the unexpected features of the SHM process.

    1. Cancer Biology
    2. Computational and Systems Biology
    Rosalyn W Sayaman, Masaru Miyano ... Mark A LaBarge
    Research Article Updated

    Effects from aging in single cells are heterogenous, whereas at the organ- and tissue-levels aging phenotypes tend to appear as stereotypical changes. The mammary epithelium is a bilayer of two major phenotypically and functionally distinct cell lineages: luminal epithelial and myoepithelial cells. Mammary luminal epithelia exhibit substantial stereotypical changes with age that merit attention because these cells are the putative cells-of-origin for breast cancers. We hypothesize that effects from aging that impinge upon maintenance of lineage fidelity increase susceptibility to cancer initiation. We generated and analyzed transcriptomes from primary luminal epithelial and myoepithelial cells from younger <30 (y)ears old and older >55 y women. In addition to age-dependent directional changes in gene expression, we observed increased transcriptional variance with age that contributed to genome-wide loss of lineage fidelity. Age-dependent variant responses were common to both lineages, whereas directional changes were almost exclusively detected in luminal epithelia and involved altered regulation of chromatin and genome organizers such as SATB1. Epithelial expression variance of gap junction protein GJB6 increased with age, and modulation of GJB6 expression in heterochronous co-cultures revealed that it provided a communication conduit from myoepithelial cells that drove directional change in luminal cells. Age-dependent luminal transcriptomes comprised a prominent signal that could be detected in bulk tissue during aging and transition into cancers. A machine learning classifier based on luminal-specific aging distinguished normal from cancer tissue and was highly predictive of breast cancer subtype. We speculate that luminal epithelia are the ultimate site of integration of the variant responses to aging in their surrounding tissue, and that their emergent phenotype both endows cells with the ability to become cancer-cells-of-origin and represents a biosensor that presages cancer susceptibility.